Literature DB >> 8916892

A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity.

J N Liu1, W Tang, Z Y Sun, W Kung, R Pannell, P Sarmientos, V Gurewich.   

Abstract

Single-chain urokinase-type plasminogen activator or pro-urokinase is a zymogen with an intrinsic catalytic activity which is greater than that of most other zymogens. To study the structural basis for this activity, a three-dimensional homology model was calculated using the crystallographic structure of chymotrypsinogen, and the structure-function relationship was studied using site-directed mutagenesis and kinetic analysis. This model revealed a unique Lys300 in pro-urokinase which could form a weak interaction with Asp355, adjacent to the active site Ser356. It was postulated that this lysine, by its epsilon-amino group, may serve to pull Ser356 close to the active position, thereby inducing the higher intrinsic activity of pro-urokinase. This was consistent with the published finding that a homologous lysine (Lys416) in single chain tissue plasminogen activator when mutated to serine induced some reduction in activity. To test this hypothesis, a site-directed mutant with a neutral residue (Lys300-->Ala) was produced and characterized. The Ala300-pro-urokinase had a 40-fold lower amidolytic activity than that of pro-urokinase. It was also stable in plasma at much higher concentrations than pro-urokinase, reflecting much attenuated plasminogen activation. Plasmin activatability was comparable to that of pro-urokinase, but the resultant two-chain derivative (Ala300-urokinase) had a lower enzymatic activity (approximately 33% that of urokinase) due to a reduction of kcat. Interestingly, the KM of two-chain Ala300-urokinase against plasminogen was 5.8-fold lower than that of urokinase, being similar to that of pro-urokinase which has a KM about 5-fold lower than urokinase. In conclusion, the hypothesis that Lys300 is a key structural determinant of the high intrinsic activity of pro-urokinase was confirmed by these studies. This residue also appears to be important for the full expression of the enzymatic activity of urokinase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8916892     DOI: 10.1021/bi9605393

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Thrombin-thrombomodulin inhibits prourokinase-mediated pleural mesothelial cell-dependent fibrinolysis.

Authors:  A V Iakhiaev; A Nalian; K Koenig; S Idell
Journal:  Thromb Res       Date:  2007-02-02       Impact factor: 3.944

2.  Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.

Authors:  R Pannell; S Li; V Gurewich
Journal:  J Thromb Thrombolysis       Date:  2017-08       Impact factor: 2.300

3.  Proteolytic properties of single-chain factor XII: a mechanism for triggering contact activation.

Authors:  Ivan Ivanov; Anton Matafonov; Mao-Fu Sun; Qiufang Cheng; S Kent Dickeson; Ingrid M Verhamme; Jonas Emsley; David Gailani
Journal:  Blood       Date:  2017-01-09       Impact factor: 22.113

4.  Mutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat stroke.

Authors:  Simone Tomasi; Paolo Sarmientos; Giada Giorda; Victor Gurewich; Alessandro Vercelli
Journal:  PLoS One       Date:  2011-07-14       Impact factor: 3.240

5.  Protease activity in single-chain prekallikrein.

Authors:  Ivan Ivanov; Ingrid M Verhamme; Mao-Fu Sun; Bassem Mohammed; Qiufang Cheng; Anton Matafonov; S Kent Dickeson; Kusumam Joseph; Allen P Kaplan; David Gailani
Journal:  Blood       Date:  2020-02-20       Impact factor: 25.476

6.  Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK.

Authors:  Ralph Pannell; Shelley Li; Victor Gurewich
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

Review 7.  Why so little progress in therapeutic thrombolysis? The current state of the art and prospects for improvement.

Authors:  Victor Gurewich
Journal:  J Thromb Thrombolysis       Date:  2015-11       Impact factor: 2.300

Review 8.  Proteolytic activity of contact factor zymogens.

Authors:  Aleksandr Shamanaev; Jonas Emsley; David Gailani
Journal:  J Thromb Haemost       Date:  2020-12-07       Impact factor: 5.824

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.